Citius Pharmaceuticals Statistics Share Statistics Citius Pharmaceuticals has 11.17M
shares outstanding. The number of shares has increased by -93.82%
in one year.
Shares Outstanding 11.17M Shares Change (YoY) -93.82% Shares Change (QoQ) 30.04% Owned by Institutions (%) 5.48% Shares Floating 10.53M Failed to Deliver (FTD) Shares 11,811 FTD / Avg. Volume 0.43%
Short Selling Information The latest short interest is 658.54K, so 3.87% of the outstanding
shares have been sold short.
Short Interest 658.54K Short % of Shares Out 3.87% Short % of Float 3.99% Short Ratio (days to cover) 3.14
Valuation Ratios The PE ratio is -3.68 and the forward
PE ratio is 0.61.
Citius Pharmaceuticals's PEG ratio is
0.
PE Ratio -3.68 Forward PE 0.61 PS Ratio 0 Forward PS 0.2 PB Ratio 2.07 P/FCF Ratio -5.15 PEG Ratio 0
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Citius Pharmaceuticals.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 0.4,
with a Debt / Equity ratio of 0.
Current Ratio 0.4 Quick Ratio 0.17 Debt / Equity 0 Debt / EBITDA -0.01 Debt / FCF -0.01 Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-1.71M Employee Count 23 Asset Turnover 0 Inventory Turnover 0.03
Taxes Income Tax 576K Effective Tax Rate -1.48%
Stock Price Statistics The stock price has increased by -90.72% in the
last 52 weeks. The beta is 1.35, so Citius Pharmaceuticals's
price volatility has been higher than the market average.
Beta 1.35 52-Week Price Change -90.72% 50-Day Moving Average 1.47 200-Day Moving Average 1.89 Relative Strength Index (RSI) 44.83 Average Volume (20 Days) 2,743,661
Income Statement
Revenue n/a Gross Profit -209.61K Operating Income -42M Net Income -39.43M EBITDA -38.64M EBIT -38.85M Earnings Per Share (EPS) -5.97
Full Income Statement Balance Sheet The company has 3.25M in cash and 262.87K in
debt, giving a net cash position of 2.99M.
Cash & Cash Equivalents 3.25M Total Debt 262.87K Net Cash 2.99M Retained Earnings -201.37M Total Assets 127.68M Working Capital -27.23M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -28.2M
and capital expenditures 0, giving a free cash flow of -28.2M.
Operating Cash Flow -28.2M Capital Expenditures n/a Free Cash Flow -28.2M FCF Per Share -2.43
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
Dividends & Yields CTXR does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for CTXR is $9,
which is 631.7% higher than the current price. The consensus rating is "Buy".
Price Target $9 Price Target Difference 631.7% Analyst Consensus Buy Analyst Count 3
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Jun 9, 2017. It was a
backward
split with a ratio of 1:15.
Last Split Date Jun 9, 2017 Split Type backward Split Ratio 1:15
Scores Altman Z-Score -3.7 Piotroski F-Score 3
